Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
about
The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsCancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Lapatinib for the treatment of breast cancer in the People's Republic of China.Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.Effects of a human compact anti-ErbB2 antibody on gastric cancer.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity.Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.Letter to the editor: "Doxorubicin and ErbB2 overexpression: another piece in the mitochondrial jigsaw".Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.
P2860
Q27011540-D033CA22-0E34-4F18-84FB-205FB7DA86FAQ28087776-894DC12D-C8FE-4035-8D1B-A875DB16F787Q30426853-B62E138B-1BC9-41E5-8581-DC3474FFF3F3Q34016491-C3A4AA37-AD67-4615-93BA-D4B41803B0B3Q35047415-1357B542-6C6A-4377-AFAE-A99960D0792EQ37131070-E0CED39A-07EE-4762-8A53-ADD094CD4B06Q37397983-12F3F045-BB64-4515-BC2A-920C13565FA1Q37586081-382A9A8F-F08E-4AE3-BD78-0113796B3609Q38995018-A784A56B-958D-4896-AA91-ECF8A2C5FEBBQ39062391-D57BD981-9FE1-4CB8-91F4-F77D5E835A34Q39185414-5C378CDC-A5AA-4564-813D-0EBE85BD32EBQ39344380-BF76028A-A110-456B-93A7-F455A29A283FQ44312601-AB3A5FAB-8E41-4E41-A7C5-499F06AC4F95Q46396418-FF2CAF8D-8A59-4E67-A970-0CDD30BCCD53Q46941129-91E7D28E-A2D1-41FC-979C-7DDA026F3474Q48228423-E0C32F5B-82AD-403A-915E-E0A2CAF194A2Q50146298-2945FF71-8056-423F-9FE0-B478F1F07690Q52714655-82F91DA8-B5FA-4C61-A9FD-026E6942F24E
P2860
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@en
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@nl
type
label
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@en
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@nl
prefLabel
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@en
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
@nl
P2093
P2860
P50
P1476
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
@en
P2093
Carmine Fedele
Giuseppe D'Alessio
Nicola Maurea
P2860
P2888
P304
P356
10.1007/S10549-011-1783-9
P407
P50
P577
2011-09-27T00:00:00Z